Please assess the completion status of the following clinical trial:

Trial Title: Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Inpatients meet the DSM-IV criteria for schizophrenia.~2. Treatment refractoriness: Failed to respond to at least two typical neuroleptics at dosage equivalent to or greater than 1000 mg/day of chlorpromazine for a period of at least six weeks.~3. Age 18-60 years.~4. Males or females.~5. Total PANSS score \>60~6. Good physical health determined by complete physical examination, laboratory tests, and EKG.~7. Capacity and willingness to give written informed consent.~Exclusion Criteria:~1. History of illicit substance abuse or dependence~2. History of clozapine intolerance (such as clinically significant leukopenia or agranulocytosis).~3. Patients with WBC count less than 3500/mm3 or ANC count less than 2000/mm3will not be included.~4. Any depot neuroleptics within 30 days before the day of randomization.~5. Epilepsy, active hepatitis, HIV positivity, or current myeloproliferative disorder. Other medical illnesses may necessitate subjects' exclusion after evaluation of individual cases by the principal investigator and other staffs. Clinical judgment will be used.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- clozapine + fluvoxamine (Type: ACTIVE_COMPARATOR): None
- clozapine + placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).